miR-486 improves fibrotic activity in myocardial infarction by targeting SRSF3/p21-Mediated cardiac myofibroblast senescence.

Hongyi Chen,Luocheng Lv,Ruoxu Liang,Weimin Guo,Zhaofu Liao,Yilin Chen,Kuikui Zhu,Ruijin Huang,Hui Zhao,Qin Pu,Ziqiang Yuan,Zhaohua Zeng,Xin Zheng,Shanshan Feng,Xufeng Qi,Dongqing Cai
DOI: https://doi.org/10.1111/jcmm.17539
2022-01-01
Journal of Cellular and Molecular Medicine
Abstract:The regulation of fibrotic activities is key to improving pathological remodelling post-myocardial infarction (MI). Currently, in the clinic, safe and curative therapies for cardiac fibrosis and improvement of the pathological fibrotic environment, scar formation and pathological remodelling post-MI are lacking. Previous studies have shown that miR-486 is involved in the regulation of fibrosis. However, it is still unclear how miR-486 functions in post-MI regeneration. Here, we first demonstrated that miR-486 targeting SRSF3/p21 mediates the senescence of cardiac myofibroblasts to improve their fibrotic activity, which benefits the regeneration of MI by limiting scar size and post-MI remodelling. miR-486-targeted silencing has high potential as a novel target to improve fibrotic activity, cardiac fibrosis and pathological remodelling.
What problem does this paper attempt to address?